HOMEPAGE The Vincenzo Pansadoro Foundation Vito Pansadoro - Urologic Laparoscopy Center Cora Sternberg - Medical Oncology Congresses Courses Publications Operations Staff News Contacts
05/09/2010
HOMEPAGE
Italian version
ABSTRACTS - VINCENZO PANSADORO FOUNDATION
Publications
Abstracts
Glossary


 

High-risk metastatic urothelial cancer: chances for cure?

Calabro F, Sternberg CN
Vincenzo Pansadoro Foundation, Clinic Pio XI, Via Aurelia 559, Rome, Italy 00165
The median survival of patients with metastatic bladder cancer treated with methotrexate, vinblastine, adriamycin, and cisplatin chemotherapy is approximately 1 year and long-term survival occurs in a small proportion of patients. Recent efforts to improve the outcome of patients with metastatic transitional cell carcinoma have focused on the identification of new drugs with single agent activity and on their incorporation into platinum-based combination regimens. Paclitaxel, docetaxel, ifosfamide and gemcitabine are among the most active new agents. A large number of phase I/II trials have evaluated these agents in two- and three-drug combination regimens. The response proportion observed with these combinations varies considerably and median survival times range from 8 to 20 months. Because it is known that pretreatment prognostic features have an impact on individual patient outcome, the variation in reported survival in patients treated with chemotherapy may be a consequence of pretreatment patient characteristics. The role of surgery in metastatic bladder cancer is still controversial. After a significant response to chemotherapy, resection of residual resistant disease may be performed with intent to cure in highly selected patients. As obtainment of complete remission is a prerequisite for long-term survival, new therapeutic strategies, such as molecular targeted small molecule therapy and monoclonal antibodies, and new molecular markers predictive of response have the potential to be incorporated into the current treatment strategies, increasing the rate of cure.
Curr Opin Urol. 2002 Sep;12(5):441-8.

Back

FOUNDATION CONGRESSES

Challenges in Laparoscopy & Robotics 2010: The European Congress of Laparoscopy
Rome, 10-12 June 2010
Challenges in Laparoscopy and Robotics: Urologist learn from frontiers specialties. Surgeons: Claude Abbou, Vincenzo Disanto, Jean-Louis Dulucq, Richard Gaston, Inderbir Gill, Till Holger, Günter Janetschek, Vito Pansadoro, Thierry Piechaud, Jens Rassweiler, Emanuel, Santoro, Jens-Uwe Stolzenburg, Roland Van Velthoven, Arnaud Wattiez, Italian surgeons
Rome, 5-6-7 June 2008
Challenges in Laparoscopy 2007. Surgeons: Claude Abbou, Renaud Bollens, Vincenzo Disanto, Richard Gaston, Inderbir Gill, Giorgio Guazzoni, Bertrand Guillonneau, Jean-Luc Hoepffner, Günter Janetschek, Vito Pansadoro, Thierry Piechaud, Roland Van Velthoven, Ingolf Türk
Bordeaux, France, June 7-8-9 2007
Challenges in Laparoscopy 2006. Guest Surgeons: Renaud Bollens, Richard Gaston, Guenter Janetschek e Peter Schulam
Rome, June 5-6-7 2006
Challenges in Laparoscopy 2005. Live Surgery: Claude Abbou, Richard Gaston, Jens Uwe Stolzenburg
Rome, June 3-4 2005
MORE CONGRESSES

ECCO 14
Barcellona, 23 - 27 Settembre 2007
home - la fondazione - centro di urologia laparoscopica - centro di oncologia medica - congressi - pubblicazioni - interventi - contatti
Copyright ©2004 all right reserved - Best viewed: Netscape - Explorer 5.5 or better - Websolution: Rita Maneri
Fondazione Vincenzo Pansadoro, Via Aurelia 559 Roma 00165 Tel.: +39 06 66418008 - +39 06 66416340
Fax: +39 06 6630771 - Email:info@fondazionevincenzopansadoro.com